The use of myeloperoxidase as a risk marker for atherosclerosis

被引：26

作者：

Nambi V. ^{[1
]}

机构：

[1] Section of Cardiology, Baylor College of Medicine, Houston, TX 77030

来源：

Current Atherosclerosis Reports | 2005年 / 7卷 / 2期

关键词：

Acute Coronary Syndrome; Endothelial Dysfunction; Vulnerable Plaque; Arterioscler Thromb Vasc Biol; Major Adverse Cardiovascular Event;

D O I：

10.1007/s11883-005-0035-z

中图分类号：

学科分类号：

摘要：

The mechanisms of atheroma formation and their ensuing complications and methods by which these can be detected have been the focus of several in vitro, in vivo, and clinical studies. Myeloperoxidase (MPO) is a microbicidal hemoprotein that serves as a part of the neutrophils' armory in host defense. However, the oxidation products generated by MPO have now been shown to be related to various stages of atheroma development. MPO and its oxidant products have been shown to be capable of modifying low-density lipoprotein cholesterol and to be enriched in human atheromas and rupture-prone plaques. Clinical studies have suggested an association between levels of MPO and the presence of coronary artery disease and endothelial dysfunction, and have shown a possible additional role to troponin in patients with chest pain. Copyright © 2005 by Current Science Inc.

引用

页码：127 / 131

页数：4

共 44 条

[11]

Hurst J.K., Myeloperoxidase-active site structure and catalytic mechanisms, Peroxidases in Chemistry and Biology, pp. 37-62, (1991)

[12]

Nauseef W.M., Myeloperoxidase deficiency- phagocytic defects, I: Abnormalities outside of the respiratory burst, Hematol. Oncol. Clin. North Am., 2, pp. 135-158, (1988)

[13]

Malech H.L., Nauseef W.M., Primary inherited defects in neutrophil function: Etiology and treatment, Semin. Hematol., 34, pp. 279-290, (1997)

[14]

Kutter D., Devaquet P., Vanderstocken G., Et al., Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit?, Acta Haemtol., 104, pp. 10-15, (2000)

[15]

Nikpoor B., Turecki G., Fournier C., Et al., A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians, Am. Heart J., 142, pp. 336-339, (2001)

[16]

Pecoits-Filho R., Stenvinkel P., Marchlewska A., Et al., A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end stage renal disease patients, Kidney Int. Suppl., 84, pp. 172-176, (2003)

[17]

Asselbergs F.W., Tervaert J.W., Tio R.A., Prognostic value of myeloperoxidase in patients with chest pain, N. Engl. J. Med., 350, pp. 516-518, (2004)

[18]

Sugiyama S., Okada Y., Sukhova G.K., Et al., Macrophage myeloperoxiodase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes, Am. J. Pathol., 158, pp. 879-891, (2001)

[19]

Carr A.C., McCall M.R., Frei B., Oxidation of LDL by myeloperoxidase and reactive nitrogen species. Reaction pathways and antioxidant protection, Arterioscler. Thromb. Vasc. Biol., 20, pp. 1716-1723, (2000)

[20]

Podrez E.A., Abu-Soud H.M., Hazen S., Myeloperoxidase generated oxidants and atherosclerosis, Free Radical Biol. Med., 28, pp. 1717-1725, (2000)

← 1 2 3 4 5 →